Sage Mountain Advisors LLC Increases Position in Thermo Fisher Scientific Inc. $TMO

Sage Mountain Advisors LLC lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 38.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,562 shares of the medical research company’s stock after purchasing an additional 982 shares during the period. Sage Mountain Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,727,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC boosted its stake in Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after acquiring an additional 988 shares in the last quarter. Revolve Wealth Partners LLC lifted its stake in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after buying an additional 20 shares during the last quarter. Exchange Traded Concepts LLC grew its position in shares of Thermo Fisher Scientific by 24.5% during the second quarter. Exchange Traded Concepts LLC now owns 2,831 shares of the medical research company’s stock worth $1,148,000 after acquiring an additional 558 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in shares of Thermo Fisher Scientific by 29.6% in the 2nd quarter. Farther Finance Advisors LLC now owns 6,544 shares of the medical research company’s stock valued at $2,653,000 after acquiring an additional 1,496 shares during the period. Finally, U.S. Capital Wealth Advisors LLC boosted its stake in Thermo Fisher Scientific by 5.6% during the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 1,779 shares of the medical research company’s stock worth $721,000 after purchasing an additional 95 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Leerink Partners upped their target price on shares of Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an “outperform” rating in a report on Wednesday, October 22nd. Wells Fargo & Company boosted their target price on Thermo Fisher Scientific from $635.00 to $675.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Friday, January 9th. Citigroup upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and raised their target price for the stock from $580.00 to $660.00 in a research note on Thursday, December 11th. Finally, Hsbc Global Res upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Monday, December 1st. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $625.47.

Thermo Fisher Scientific Trading Down 1.4%

Shares of Thermo Fisher Scientific stock opened at $609.76 on Tuesday. The company has a 50-day moving average of $587.17 and a two-hundred day moving average of $526.57. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $629.87. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. The stock has a market cap of $229.09 billion, a PE ratio of 35.23, a price-to-earnings-growth ratio of 4.07 and a beta of 0.91.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The business had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company’s revenue was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, January 15th. Investors of record on Monday, December 15th were paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend was Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.94%.

Thermo Fisher Scientific announced that its board has initiated a stock repurchase program on Thursday, November 6th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical research company to buy up to 2.4% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling

In other news, COO Michel Lagarde sold 22,046 shares of the stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $563.56, for a total value of $12,424,243.76. Following the sale, the chief operating officer directly owned 84,117 shares in the company, valued at $47,404,976.52. This represents a 20.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 7,250 shares of the company’s stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $566.10, for a total value of $4,104,225.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $64,400,668.20. The trade was a 5.99% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 149,271 shares of company stock valued at $86,507,282. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.